EUVIMEDOtkrijte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer’s Disease: Mechanisms, Clinical Progress, and Future Strategies

InWook Park, Donghwan Lee, Rachel Sunmin Hong, Hye Yun Kim, YoungSoo Kim

Experimental Neurobiology · 2026-04-30 · 35 (2) · 57-80

DOI: 10.5607/en25040 ↗

At a glance

Übersichtsarbeit in Experimental Neurobiology, published online on 2026-03-30. Written by InWook Park and 4 co-authors. Institution: Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea. Cited 4 times so far (Crossref); 162 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Korea Dementia Research Center, Ministry of Health and Welfare, Ministry of Science and ICT, South Korea.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Alzheimer's disease (AD) imposes a growing burden on global healthcare systems. Current therapeutic interventions primarily alleviate cognitive and functional symptoms but have limited impact on the underlying neurodegenerative processes driving disease progression. This underscores the urgent need for treatments that target the pathogenic mechanisms of the disease. Advances in monoclonal antibody therapies against amyloid-β (Aβ) provide encouraging evidence for disease modification, though challenges related to dosing, cost, and safety constrain their broader application. Small molecule therapeutics represent a compelling alternative owing to advantageous properties such as enhanced brain penetration, oral bioavailability, and suitability for long-term administration in elderly patients. Building on these attributes, this review evaluates small molecule therapeutics as promising candidates for AD treatment. It summarizes small molecule compounds targeting Aβ across mechanisms that include modulating production, inhibiting aggregation, disassembling aggregates, enhancing clearance, and mitigating neurotoxicity. A comprehensive assessment of current data emphasizes the importance of continued research to overcome ongoing challenges and fully leverage the potential of small molecules. The limited number of candidates in late-stage clinical trials indicates that substantial efforts are still required to identify and refine effective agents. Continued investigation into their mechanisms and optimization of compound profiles will advance the development of small molecule-based therapies for AD.

Subjects

Author keywords

Alzheimer diseaseAmyloid beta-peptidesClinical trials as topicDrug therapyProtein aggregationpathological

Authors and institutions

  • Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea.
  • Pharmaceutical Sciences, University of Wisconsin, WI 53705, USA.
  • Department of Integrative Biotechnology, Yonsei University, Incheon 21983, Korea.
  • Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University, Seoul 03722, Korea.
  • POSTECH-Yonsei Campus, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.
  • Amyloid Solution Inc., Seongnam 13486, Korea.

Funding

  • Korea Dementia Research Center
  • Ministry of Health and Welfare
  • Ministry of Science and ICT, South Korea
  • National Research Foundation of Korea
  • Korea Institute for Advancement of Technology
  • Ministry of Trade, Industry, and Energy

Cite

APA

Park, I., Lee, D., Hong, R. S., Kim, H. Y., & Kim, Y. (2026). Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer’s Disease: Mechanisms, Clinical Progress, and Future Strategies. Experimental Neurobiology, 35(2), 57-80. https://doi.org/10.5607/en25040

Vancouver

Park I, Lee D, Hong RS, Kim HY, Kim Y. Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer’s Disease: Mechanisms, Clinical Progress, and Future Strategies. Experimental Neurobiology. 2026;35(2):57-80. doi:10.5607/en25040

BibTeX
@article{Park2026,
  author = {Park, InWook and Lee, Donghwan and Hong, Rachel Sunmin and Kim, Hye Yun and Kim, YoungSoo},
  title = {Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer’s Disease: Mechanisms, Clinical Progress, and Future Strategies},
  journal = {Experimental Neurobiology},
  year = {2026},
  volume = {35},
  number = {2},
  pages = {57--80},
  doi = {10.5607/en25040}
}
Start for free →